Abstract
Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/ diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target ( < 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.
Keywords: Peripheral arterial disease, risk factors, dyslipidemia, lipid lowering, statins, prevention
Current Drug Targets
Title: Lipid Management and Peripheral Arterial Disease
Volume: 8 Issue: 4
Author(s): S. S. Daskalopoulou, M. E. Daskalopoulos, D. P. Mikhailidis and C. D. Liapis
Affiliation:
Keywords: Peripheral arterial disease, risk factors, dyslipidemia, lipid lowering, statins, prevention
Abstract: Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/ diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target ( < 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.
Export Options
About this article
Cite this article as:
Daskalopoulou S. S., Daskalopoulos E. M., Mikhailidis P. D. and Liapis D. C., Lipid Management and Peripheral Arterial Disease, Current Drug Targets 2007; 8 (4) . https://dx.doi.org/10.2174/138945007780362737
DOI https://dx.doi.org/10.2174/138945007780362737 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Current Molecular Medicine Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Editorial [Hot Topic: Modifying Coronary Risk Factors: C-Reactive Protein,Haemostatic Factors and Cardiovascular Risk (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Integrating Care for Older Adults with Cognitive Impairment
Current Alzheimer Research Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Combating Obesity by Targeting Nuclear Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Current Cancer Drug Targets The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued)